Detalhe da pesquisa
1.
Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours.
Eur J Nucl Med Mol Imaging
; 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38528164
2.
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours.
Eur J Nucl Med Mol Imaging
; 51(1): 183-195, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37721581
3.
AbobotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of spinal cord injury or multiple sclerosis etiology: Pooled analysis of two phase III randomized studies (CONTENT1 and CONTENT2).
Neurourol Urodyn
; 42(1): 153-167, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36321799
4.
Exploring the Relationship Between Clinical Presentation in Hallux Valgus and Response to AbobotulinumtoxinA Treatment.
J Foot Ankle Surg
; 62(3): 556-562, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36804286
5.
Pain Reduction With AbobotulinumtoxinA for the Treatment of Hallux Valgus in Adult Participants: Results of a Randomized and Placebo-Controlled Phase 2 Trial.
J Foot Ankle Surg
; 62(2): 244-253, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36335048
6.
Liquid AbobotulinumtoxinA: Pooled Data From Two Double-Blind, Randomized, Placebo-Controlled Phase III Studies of Glabellar Line Treatment.
Dermatol Surg
; 48(11): 1198-1202, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36206385
7.
Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-Label Study.
Aesthet Surg J
; 42(3): 301-313, 2022 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34472596
8.
Significantly Increased Patient Satisfaction Following Liquid Formulation AbobotulinumtoxinA Treatment in Glabellar Lines: FACE-Q Outcomes From a Phase 3 Clinical Trial.
Aesthet Surg J
; 40(9): 1000-1008, 2020 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31550352
9.
Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines.
Aesthet Surg J
; 40(1): 93-104, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30893430
10.
Liquid Formulation of AbobotulinumtoxinA Exhibits a Favorable Efficacy and Safety Profile in Moderate to Severe Glabellar Lines: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trial.
Aesthet Surg J
; 38(2): 183-191, 2018 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-28200002
11.
Corrigendum to: Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines.
Aesthet Surg J
; 41(11): 1338, 2021 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33739363
12.
Response to "Facial Line Outcomes (FLO-11) and Facial Line Satisfaction Questionnaire (FLSQ) Meet FDA PRO Guidance".
Aesthet Surg J
; 40(12): NP708-NP709, 2020 11 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32960940
13.
Goal Attainment after Treatment with Abobotulinumtoxina and a Tailored Home Therapy Programme in Children with Upper Limb Spasticity: Descriptive, Exploratory Analysis of a Large Randomized, Controlled Study
J Rehabil Med
; 54: jrm00349, 2022 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36306168
14.
Efficacy and Safety of AbobotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Incontinence Performing Regular Clean Intermittent Catheterization: Pooled Results from Two Phase 3 Randomized Studies (CONTENT1 and CONTENT2).
Eur Urol
; 82(2): 223-232, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35400537
15.
Safety and pharmacodynamics of a novel recombinant botulinum toxin E (rBoNT-E): Results of a phase 1 study in healthy male subjects compared with abobotulinumtoxinA (Dysport®).
J Neurol Sci
; 407: 116516, 2019 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31655410
16.
Importance of lack of interest in patients with mild cognitive impairment.
Am J Geriatr Psychiatry
; 16(9): 770-6, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18757769
17.
Frontal Assessment Battery is a marker of dorsolateral and medial frontal functions: A SPECT study in frontotemporal dementia.
J Neurol Sci
; 273(1-2): 84-7, 2008 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18938766
18.
AbobotulinumtoxinA Efficacy and Safety in Children With Equinus Foot Previously Treated With Botulinum Toxin.
Pediatr Neurol
; 82: 44-49, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29625849
19.
Dose-Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study.
PM R
; 10(1): 1-10, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28634000
20.
Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia.
Brain
; 129(Pt 11): 3051-65, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17071924